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In his inaugural lecture in this series, Professor Ken Bag-
shawe hoped that his successors 'will not shrink from contro-
versy or unwheeling contemporary bandwagons' (Bagshawe,
1989). The Association of Cancer Physicians has now asked
me to inspect, on their behalf, one of the biggest of all
bandwagons, modem basic cancer research. You would not
wish me to unwheel, even if I could, a vehicle with so many
passengers, but you are concerned about its direction and its
rate of progress, an impatience ironically acknowledged in
Professor Bagshawe's original title for his lecture; 'Whilst
waiting for the human genome to be mapped'. Like all
mechanics, I am underneath this bandwagon looking up and,
despite erratic steering and a lumbering forward motion, it
seems quite capable of reaching its destination if carefully
handled. I hope to persuade you of this by examining, firstly,
our current understanding of cancer biology, secondly, the
prospects this offers for better management and, finally, ways
to encourage the translation of understanding into practice.
The biologist's view ofcancer
Like most long-standing endeavours, the present status of
basic cancer research is only fully explicable by reference to
its history. The original impetus to know more about cancer
came from the problems of managing the cancer patient and
laboratory investigations were intended, directly or indirectly,
to aid this management. The knowledge gained from this
'top down' approach and, in particular, the finding that a
single cancer cell could form a tumour in a recipient animal,
led to the cancer cell supplanting the cancer patient as the
unit of interest to many biologists. There developed the large
body of 'bottom up' cancer research, that tackled problems
generated at the cellular level and whose reductionist view
was greatly abetted by the development of in vitro cell culture
systems, particularly those exploiting tumour viruses and the
power of classical molecular genetics (Figure 1).
This latter approach has proved enormously fruitful, lead-
ing in turn to the identification of viral genes that induce
neoplasia, to the discovery of normal cell homologues (proto-
oncogenes) for some of these viral oncogenes and to the
implication of proto-oncogene mutations in many naturally-
occurring cancers. These findings, in total, impressively
validate the concept that somatic mutations in the neoplastic
cell lineage underlie the altered growth and behaviour that
typify cancer. Moreover, functions were assigned to many
proto-oncogene products that seemingly explained their abil-
ity to perturb normal cell growth and behaviour. It has
become axiomatic that genes whose alterations contribute to
neoplasia encode products that play a role in the complex
processes by which a cell perceives and responds to its
environment. 'Oncoproteins' have variously been identified as
molecules transmitting signals between cells, as the receptors
for these ligands (either on the cell surface or inside the cell),
as components of second messenger pathways or as nuclear
proteins that mediate the response of the cell genome (Figure
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2). We might also expect oncoproteins to contribute to events
that follow from changes in genomic activity, but clear cut
examples of changes in these 'effector' pathways are so far
lacking, in contrast to the probable situation with tumour
suppressor genes (see below, Fearon et al., 1990; Pignatelli &
Bodmer, 1988). The signalling pathways in which onco-
proteins have been implicated have generally been those
favouring cell multiplication at the expense of terminal differ-
entiation (Figure 2) but it must be emphasised that in no case
(with the possible exception of oncoproteins cognate with
intracellular hormone receptors) do we understand in detail
the circuits disrupted by oncogenic mutations.
The success of the reductionist approach warrants its con-
tinuation for as long as we can ask significant questions
about the cancer cell and the issue of matching this research
to the management of the patient is rightly irrelevant to its
justification. However, over the past decade the molecular
biologist has come to appreciate the complexity of neoplasia
that has long been apparent to the pathologist and physician
and the limitations of pure reductionism have been exposed.
The viral oncogene paradigm and its conceptual descendants
provide an inherent bias to the detection of genetic altera-
tions that, on their own, confer on a normal cell pheno-
typically dominant altered growth. Attention has thus been
diverted from, and is only recently returning to, the following
crucial facets of neoplasia.
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Figure 1 The structure ofcancer research, depicted as a pyramid
whose apex is the desired solution to managing all or part of the
problem. Questions initially posed by attempts at patient man-
agement stimulated both clinical research (top of pyramid) and
'top down' laboratory work (filled arrowheads). The latter soon
led to broadly-based, self-justifying 'bottom up' investigations,
based on the cancer cell (cross-hatched arrowheads). The two
types of laboratory work were, until recently, generally distin-
guishable in concepts and techniques, but they are now merging
as the principles of basic research are applied to problems posed
by the patient and should soon impinge on clinical practice.
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Figure 2 Schematic of the pathways that control cell growth and
differentiation. The proliferation-promoting pathway shows a sig-
nal (ligand) binding to a transmembrane receptor to generate a
second message that leads, directly or indirectly, to a change in
nuclear function. An example is the binding of epidermal growth
factor to its receptor, the latter being a tyrosine protein kinase
cognate with the erb-B oncogene. The differentiation-promoting
pathway shows an example of a signal recognised by an intracel-
lular receptor that can itself bind to DNA, an instance being
steroid hormone receptors (in the diagram the receptor is nuclear
but it may frequently be cytoplasmic). These examples are only
two of many possible variations that can operate in either type of
pathway. The pathways themselves are not necessarily distinct
and opposing, as shown in this simple diagram, but may com-
municate and a single component (such as transforming growth
factor-P or leukaemia inhibitory factor) can contribute to
different pathways in different cell environments (from Wyke,
1990, with permission).
more, the perceived functional contrast between the two sets
of genes is likely, for a variety of reasons, to be somewhat
artificial. The fine-tuning of cell homeostasis will require
extensive 'cross-talk' between pathways that promote or
inhibit a given aspect of cell activity and natural parsimony
may dictate that similar proteins have different functions in
different contexts (the behaviour of transforming growth
factor-P (TGF-P) is a good example of this, see below).
Furthermore, the distinction between oncogene and tumour
suppressor gene may be operational rather than absolute,
and the same gene may be assigned to both categories,
depending on the mutations it has suffered. The best example
of this is the p53 gene (Lane & Benchimol, 1990) but since its
behaviour is still incompletely understood it may be better to
illustrate the point with a purely hypothetical case (Figure 3).
Suppose a protein, A, modifies a substrate, B, the product B*
being essential for a process of terminal differentiation
(Figure 3(i)). Mutations, A', that prevent A binding to B will
be phenotypically recessive (Figure 3(ii)) but, if the wild type
A allele is also mutated or lost, differentiation will be blocked
and neoplasia may ensue, a characteristic scenario with
tumour suppressor gene mutations. Other loss of function
mutations, A", that lead to a high affinity binding of B, but
(i) Normal
A
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(ii) Recessive mutation
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*- Differentiation
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Tumour evolution The multistep character of tumour deve-
lopment was the first focus for molecular biologists grappling
with the more complex aspects of neoplasia (Weinberg,
1989). Information on this point from the well-tried experi-
mental systems retained, however, the bias to identifying
what were then considered to be dominantly acting onco-
genes.
Tumour suppression The concept that recessive (loss of func-
tion) mutations contribute as much, or more, to neoplasia
than dominant (change of level or function) mutations is now
a major bandwagon in its own right (Klein, 1987). The
tumour suppressor genes that are the targets for such muta-
tions were first highlighted in model systems but their recent
prominence is due to studies on naturally occurring tumours
in which, moreover, their mutations have been shown to
contribute to the multistep evolution of cancer (Fearon et al.,
1990). These findings exemplify a significant trend in which
the technologies of the reductionist approach are increasingly
applied to problems of 'top down' cancer research to reveal
concepts that were inaccessible to earlier experimental
systems. These challenges stimulate, at the active interface
between 'bottom up' and 'top down' studies, the develop-
ment of more sophisticated models, such as transgenic
animals bearing specific mutations in oncogenes or tumour
suppressor genes.
There is growing evidence that tumour suppressor gene
and oncogene functions occupy comparable niches in cellular
physiology, with the former mediating processes that favour
differentiation over cell multiplication (Figure 2). Further-
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Figure 3 Three types of mutation that might be implicated in
neoplasia. This hypothetical example postulates (i) a protein, A,
whose normal function is to convert a target molecule, B, into a
modified product, B*, that is required for differentiation. (ii) A
mutant, A', that cannot interact with B would be recessive,
impeding differentiation only if the normal protein is lost. By this
criterion A would be considered a typical tumour suppressor
protein. (iii) If a mutant protein, A", has lost its normal function
but displays an abnormal affinity for B, this would have a
dominant negative effect. It would be relieved if there is enough
non-sequestrated B protein for conversion to B* by the wild type
A product. (iv) A mutation that, for example, changes the loca-
tion or regulation of active A might expose it to a target, related
to B, but responsible for a proliferative stimulus that overrides
the continuing signal to differentiate. The mutant protein, A"', is
thus equivalent to a dominantly acting oncoprotein.
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no modification, could have a dominant negative effect, lead-
ing to a block in differentiation that is, however, partially
relieved by the presence of wild type A product (Figure
3(iii)). Finally, Figure 3(iv) exemplifies one of several types of
mutation whose effect would be dominant even in the pre-
sence of wild type A. In this case a mutant protein of altered
location (A"') binds to a local B-related substrate, C, that in
modified form mediates a cell proliferative signal that may or
may not preclude acquisition of differentiated characteristics.
Changes in cell behaviour Most genetic alterations that have
been implicated so far in cancer have had effects on cell
multiplication, yet it is the concomitant changes in cell
behaviour that pose the greatest challenges in managing the
disease. The interactions of tumour cells with adjacent nor-
mal cells (and, through signalling molecules, with distant
normal cells), and the tumour cells' ability to invade locally,
disseminate, attach and grow in ectopic locations and furnish
themselves with a blood supply are all important phenomena
for which our knowledge is rudimentary (Paraskeva & Wil-
liams, 1990; Sobel, 1990; Weinberg, 1989). In part this is
because most of these facets of tumour biology are only
properly examined in the whole organism, a difficult theatre
of operations for the cell and molecular biologist. Here again
we might hope that studies on natural tumours will provide
useful correlations between genetic alterations and tumour
behaviour that, in turn, will permit the design of appropriate
model systems for further investigation.
Non-genetic alterations A central thesis in modern cancer
research has been the importance of somatic (and sometimes
germline) mutations in the tumour lineage. Without decrying
the importance of mutation, it seems that normal metazoan
development involves changes in cellular phenotype, usually
without alterations in genotype, that are largely irreversible
and thus embody the stability required to play a role in
neoplasia. There is only sparse information on whether
mechanisms that regulate gene activity in the long term, such
as transitions in chromatin configuration and DNA methyla-
tion (Goelz et al., 1985), have any significance for cancer
causation. These are, indeed, difficult areas of study but I
suspect that their relative neglect, like those of the other
topics outlined above, stems from the undoubted success of
mainstream reductionist studies.
To sum up, the success of the past 20 years of basic cancer
research has taken us to a new level of understanding of
cancer biology. For the first time we have a clear picture of
what awaits discovery and, although our ignorance is daun-
ting, some cancer biologists are already trying to rebuild the
process in all its complexity even as their colleagues continue
to disassemble it. It is undoubtedly early days to predict
confidently how this growth in basic understanding will affect
cancer patients but, armed with examples from the literature
and the work of my colleagues, I will indicate where applica-
tions can be anticipated.
Applying cancer biology to cancer management
Even incomplete basic knowledge expands the options for
intervention in cancer (Cairns, 1989) and opportunities can
be foreseen for improving management of all aspects of the
problem.
Cancer avoidance Our discussion so far has been about
mechanisms, rather than causes, of cancer and might be
thought of little relevance to preventing the disease. How-
ever, studies on mechanism have provided information in
several areas germane to avoidance.
Tumour viruses, which are risk factors in about 10-20%
of human cancers (zur Hausen, 1986), have been a favourite
tool of the basic biologists and our appreciation of their
clinical significance has benefited greatly from this attention.
Prophylactic vaccines, whose development required an inti-
mate knowledge of the viruses, have been developed for
oncogenic herpesviruses, papillomaviruses and retroviruses of
animals and for hepatitis B virus of man. Vaccines against
the other human viruses implicated in cancer, Epstein Barr
virus and papilloma- and retroviruses, are at varying stages
of research or development. We must bear in mind, however,
that the rationale for developing such vaccines is not neces-
sarily straightforward (Wyke, 1990). Viruses implicated in
human cancer are generally widespread agents and neoplasia
is characteristically associated with chronic infection, acquir-
ed early in life and accompanied by immune impairment and
exposure to co-carcinogens. A significant risk of neoplasia
may thus only exist for a subset of the population and there
may be a lag of a generation before benefits accrue from
immunisation. These factors mean that the benefits of vac-
cination must be weighed carefully against its costs and risks
unless, as with hepatitis B, the virus poses a major non-
neoplastic risk to health.
Consideration of viral carcinogenesis leads us to another
aspect of cancer avoidance that may benefit from deeper
biological understanding. Controlled breeding and intensive
husbandry in the domestic fowl have shown that suscepti-
bility to the commonest form of cancer is widespread and
inherited in a dominant fashion. The reason has been known
for 30 years. In domestication, the retroviruses of the avian
sarcoma/leukosis complex are the predominant carcinogens
and they can only infect birds that express cellular receptors
for the viral envelope glycoproteins. Such clear-cut predis-
position to neoplasia is only rarely seen in human popula-
tions that are generally outbred and exposed to varying
environmental influences, but the possibility of more subtle
and ubiquitous variations in inherited proneness to cancer is
now receiving attention (for example, Law, 1990). If we
understand the undoubtedly complex factors that determine
such variations then we can tackle the even more difficult
problem of deciding how to use such knowledge.
In the even longer term, there are two other prospects for
cancer avoidance, and the fowl again provides an example of
the first. If a strain ofchickens is susceptible to virus-induced
neoplasia because it expresses the cellular receptor for a
common retrovirus type, then it is possible to abrogate this
susceptibility by manipulation of the chicken genome. Clas-
sical breeding has achieved this in some instances but trans-
genesis now provides, in theory, two other options. Site
specific recombination can be used to ablate the gene enco-
ding the viral receptor or the receptor can be blocked by
introducing into the bird a vector expressing the viral enve-
lope glycoprotein. We do not know, however, the physio-
logical role of the receptor molecule, so we are unable to
predict the consequences of either its loss or permanent
association with the viral glycoprotein ligand. Such uncer-
tainties may only be resolved by studying the transgenic
animal and thus practical, as well as ethical, considerations
may largely limit this type of intervention to veterinary sub-
jects.
The other long term prospect is the improved detection of
environmental carcinogens. At present a battery of tests are
used to predict carcinogenicity or mutagenicity but these do
not examine the precise pathways by which carcinogens exert
their effects. However, once the details of carcinogenesis are
understood it may be possible to devise tests that predict
more exactly the consequences of exposure to a given agent.
This knowledge will help in deciding appropriate safety cont-
rols as well as in monitoring the effects of untoward
exposure. In a broader context, and one that is even more
difficult to predict, a greater understanding of mechanisms
may help in elucidating the causes of those common cancers
in which environmental influences are suspected but not
defined. This should be a very important goal, but epide-
miological successes do not necessarily lead to improved
cancer management if their implications run counter to social
and political trends. Political considerations also apply to the
next aspect of management that will benefit from basic
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Screening and early detection ofcancer I am not qualified to
comment on the economic, social and psychological ramifi-
cations of detecting cancer at an earlier stage but, objectively,
early detection may increase, and should never reduce, the
patient's lifespan. However, although biologists may leave
others to decide the desirability of screening in specific in-
stances, they have to recognise that any potential screening
strategies spawned by basic research should be simple, cheap,
precise, easy to interpret and acceptable to the population to
be screened.
These are severe and sometimes opposing constraints to
place on the detection of a complex and subtle disease in
which a series of genetic alterations lead to either qualitative
or quantitative changes in gene products. Thus, simplicity,
economy and, to a lesser extent, precision, are best satisfied
by screening for gene products that invariably undergo
tumour-specific qualitative changes that can be detected with
high sensitivity, probably by immunological means. Accept-
ability would be enormously enhanced if these changes could
be perceived in samples obtained by non-invasive means,
presumably biasing this approach to tumours of the exocrine
organs and the respiratory, alimentary and urogenital tracts
where, fortunately, many important human cancers occur. It
will not be easy to discover tumour cell products with these
stringent characteristics.
In contrast, the most precise and easily interpreted changes
are those to the DNA of tumour cells, but it has been
difficult to see how genetic alterations to a small number of
cells could be detected with high sensitivity and patient com-
pliance. The rapid exploitation of the polymerase chain reac-
tion (PCR) in the past few years looks set to solve the
problem of sensitivity if not acceptability (McCormick,
1989). However, just as detailed knowledge of protein altera-
tions are essential to devising immunological probes, so we
must understand preci-sely the sites of mutations in tumours
to design oligonucleotide primers for PCR. The inescapable
conclusion is that more basic information is needed to under-
pin new screening strategies.
Diagnosis and prognosis Even without the development of
new early detection methods, existing screens for carcinoma
of the cervix and breast will produce false positives that need
rapid resolution, adding to an important demand on expert
diagnostic services. There is thus a clear incentive to ask
whether our new knowledge of cancer will allow diagnosis to
become easier and cheaper without sacrificing its accuracy. It
is also important to know whether prognosis can be made
more precise, particularly in predicting response to therapy
and thus contributing more to the management of the
disease. In addition there is a need for more effective moni-
toring of the establishment and maintenance of remission in
patients already receiving treatment.
The approaches which basic research can bring to bear on
these needs are similar to those which can be applied to early
detection, notably antibody probes for tumour-specific pro-
teins and nucleic acid probes for genetic alterations. How-
ever, applications in diagnosis and prognosis are greater and
constraints are less. Indeed, although monitoring remission
for incipient relapse shares many of the problems of early
detection, it is relatively free of the need for simplicity, low
cost and patient compliance and can, moreover, be tailored
to individual patients. Thus, overall, this is the first facet of
cancer management in which our new biological understand-
ing is likely to have an impact. Monoclonal antibodies for
immune histochemistry are readily used and may soon be
supplemented by 'single domain antibodies', themselves a
result of exploiting PCR technology (Ward et al., 1989). The
detection of nucleic acid changes, be they characteristic RNA
transcripts or genomic DNA altered by deletions, point muta-
tions or translocation have formerly required techniques that
were relatively complex for adoption by pathology labora-
tories. However, attempts to simplify their use by devising
various in situ hybridisation techniques may themselves soon
be supplanted by the widespread adoption of PCR.
At present, indeed, the limitations to applying molecular
biology to diagnosis are not in the techniques but in our
ability to interpret the results, and until our understanding
is more profound that will restrict implications for cancer
management. One example illustrates these points. The Phila-
delphia chromosomes are produced by translocations that
fuse the 5' end of the phl (BCR) gene on chromosome 22 to a
decapitated c-abl gene from chromosome 9, the hybrid gene
producing mRNA transcripts and protein products that are
unique to chronic myeloid leukaemia (CML). Although the
breakpoints on chromosome 22 in CML occur in a limited
region (Figure 4a), they do show variations that modify the
structure of the phl-abl hybrid gene and several groups have
tried to correlate these variations with the clinical course of
CML. Birnie et al. (1989) have discussed these studies and
proposed, as a consensus, that breakpoints with a more 5'
location in phl are found more frequently in patients with a
longer chronic phase to the disease (Figure 4b), although this
conclusion remains in dispute (Jaubert et al., 1990). Clearly,
more basic information is needed to decide whether and how
chromosome 22 breakpoint positions influence CML prog-
nosis and only then can it be determined whether this in-
formation will influence patient management.
Aids to existing cytotoxic therapies Cancer physicians are
most excited by the scope basic understanding of cancer
offers for new and improved treatments. Prospects for
therapy are of two types; adjuncts to existing treatments or
radically new approaches to treatment, the former probably
entering clinical research and practice before the latter.
Some ways of improving existing cytotoxic chemotherapy
or radiotherapy are listed in Table I. Most of the gambits
mentioned evolved from 'top down' research in chemistry,
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Figure 4 a, The structure of various hybrid genes and hybrid
transcripts between phl(BCR) (chromosome 22, open boxes) and
c-abl (chromosome 9, filled boxes). Introns in the genes are
shown by straight lines. The question mark indicates that the
transcript depicted has yet to be found and, if it does exist, the
coding region of the ablportion would be expected to be out of
frame with the phlportion. The boundary between 5' breakpoints
(to the left) and 3' (to the right) is arbitrarily located at about the
middle of the intron between phi exons 14 and 15. b, Duration of
chronic phase for Philadelphia chromosome positive CML
patients with either 5' or 3' breakpoint (from Mills et al., 1989).BASIC RESEARCH AND THE MANAGEMENT OF CANCER 345
Table I Aids to existing cytotoxic therapies
1. Increase dose to tumour
(a) Improved pharmacology/pharmacokinetics of cyto-
toxins.
(b) Targetting - Homing or local delivery, eg 2-stage
antibody directed enzyme prodrug therapy, bioreduc-
tive activation.
2. Increase tumour cell susceptibility
(a)
(b)
(c)
Radio/chemosensitisers.
Stimulate tumour cell growth.
Avoid/counteract inherent or acquired drug resistance
(i) Mediated by P glycoprotein.
(ii) Other mechanisms, eg Cytochrome P450,
glutathione S-transferase.
3. Spare normal tissues
(a) Targetting to tumour (above).
(b) Reduce specific toxicities
(i) Modified cytotoxins.
(ii) Protective drugs.
(c) Reduce damage to replicating tissues - general or
specific inhibitors.
(d) Encourage normal tissue regeneration - use of
cytokines.
chequered history and is now attracting renewed interest. In
part this reflects our better understanding both of immuno-
modulatory molecules and of the molecular biology of the
major histocompatibility complex (MHC) and its possible
role in mediating antitumour responses. Current approaches,
in animals and in man, centre around three strategies
(Napolitano et al., 1989), each of which addresses different
aspects of the presumed host T-cell recognition of tumour-
specific antigens in association with MHC class I molecules.
They might thus be used to complement one another.
1. The use of interferons to increase the frequently low
MHC class I antigen expression in tumour cells.
2. The use of the lymphokine interleukin-2, with or without
adoptive transfer of tumour infiltrating lymphocytes or lym-
phokine activated killer cells.
3. Attempts at immune potentiation, increasing the host's
response to putative tumour-specific antigens by, for in-
stance, pre-immunisation with tumour cells bearing up-regu-
lated MHC class I antigens. It is interesting in this context
that injection of some structural proteins of bovine papillo-
maviruses is effective in inducing rejection of virus-induced
papillomas (Campo & Jarrett, personal communication). A
comparable effect with the human papillomaviruses impli-
cated in cervical carcinoma could be very beneficial.
pharmacology and cell biology and, since they derive neither
concepts nor technologies from reductionist cancer research,
they are largely beyond my remit. There are, nonetheless,
several strategems in Table I that have benefited, or may
benefit, from 'bottom up' research.
1. In using antibody directed mechanisms to target chemo-
therapy to tumours it is clearly helpful to have as the target a
molecule that is expressed universally on clonogenic tumour
cells and is seldom found on other cells. As I mentioned
when discussing early diagnosis, molecules with this degree of
tumour specificity will be few, if they exist at all. Aiming for
fulfilment of the first requirement only, the molecules most
likely to be expressed on all tumours of a given type are
those encoded by genes whose alterations are causally linked
to neoplasia or, possibly, molecules with a close metabolic
relationship to the former. An intimate knowledge of aber-
rant tumour biochemistry will be needed to identify candi-
dates.
2. The idea of stimulating tumour cell growth to increase its
susceptibility is an old one that has not been generally
accepted. If we had a complete picture of the growth controls
that impinge on a tumour, this concept might merit re-
examination. It is also worth noting that our knowledge of
drug resistance has gained greatly from the application of
molecular biology and a greater understanding of this
phenomenon may suggest ways to inhibit specifically the
proteins mediating resistance, along lines to be discussed
below.
3. The protection of normal tissues through the therapeutic
use of natural growth inhibitory molecules is a potentially
rewarding field of study. For example, an inhibitor of
haemopoietic stem cell activity detected in vivo has been
purified, through the use of an in vitro stem cell assay, and
characterised (Graham et al., 1990). This molecule, by inhib-
iting bone marrow stem cell growth, may protect them from
cytotoxic drugs, although it should be remembered that
many drug regimes affect the haemopoietic progenitor cell
compartment rather than stem cells. It is possible that the
inhibitor may also affect stem cells of other lineages, broad-
ening the scope for its therapeutic use.
4. A strategy that is currently receiving much attention is
the use of growth stimulatory molecules to encourage the
regeneration of tissues damaged by cytotoxic agents. The use
of haemopoietic colony stimulating factors to achieve rapid
and effective recovery of the progenitor cell compartment is a
good example of this approach (Crowther et al., 1990).
Potential new therapies: immunotherapy It is wrong to de-
scribe immunotherapy as a new approach, but it has had a
Potential new therapies: reimposing homeostasis in tumour
cells. If most basic cancer researchers were asked to define
their long-term aims, the goal of replacing uncertain and
unpleasant cytotoxic treatments with biochemical manipula-
tions that 'reform' the behaviour of tumour cells would rank
high among their amibitions. Possible routes to achieving this
end are outlined in Table II, from which it can be seen that
the strategies are heavily dependent on the knowledge
acquired from reductionist studies. Moreover, since these
gambits are aimed at the very changes that render a cell
neoplastic there seem few ways for the tumour to become
refractory to treatment without, at the same time, ceasing to
grow or behave abnormally. Nonetheless, we should remem-
ber that the concept of reimposing homeostasis in its broader
sense is not novel, having been applied in the use of anti-
endocrines to treat hormone responsive tumours.
We shall consider in turn the options listed in Table II.
1. A popular view of neoplasia represents it as resulting
from a failure to complete a normal cell differentiation prog-
ramme. If true, the corollary of this concept is that neoplasia
would be cured by inducing the tumour cells to differentiate.
The processes that determine normal differentiation are not
fully understood for any lineage but roles have been postu-
lated for small molecules, such as retinoic acid, dihydroxy
vitamin D3 and cyclic AMP, as well as for protein factors.
The effects of many such agents have been tested on various
tumour cells and some were, indeed, first identified as activ-
ities that inhibited tumour cell growth, but their therapeutic
exploitation is not straightforward.
First, as alluded to earlier, the activity of factors im-
plicated in differentiation can be very dependent on their
Table 11 Potential new therapies: reimpose homeostasis
(a) Inducers ofdifferentiation
Cyclic AMP, retinoic acid, DIA/LIF
(b) Inhibitors ofactivated oncogenes (mutant or overexpressed)
Antisense oligonucleotides aimed at DNA or mRNA
Ribozymes
(c) Inhibitors ofactivated oncoproteins
(i) Block biosynthesis
(ii) Block effectors or regulators of function
(iii) Compete for active site on protein
(iv) Compete for substrates
(d) Replacement ofinactivated twnour suppressors
(i) Replace gene
(ii) Replace or substitute gene product346 J.A. WYKE
context. For example, leukaemia inhibitory factor (LIF) that
promotes differentiation of the mouse MI myeloid leukaemia
is identical to a factor that promotes growth of DA cells,
another mouse leukaemia. Moreover, the differentiating
inhibitory activity (DIA) that maintains mouse embryonal
stem cells in a totipotent state is also the same as, or highly
related to, LIF (Gough & Williams, 1989).
A second concern is that some neoplasias may arise in part
because they no longer respond to normal induction of
differentiation, so they will be refractory to the therapeutic
use of inducers. TGF-P, first described as a transformed cell
growth factor, is a growth inhibitor in most contexts but
some tumours do not respond to it because of changes at a
receptor or post- receptor level. Indeed, the tumour-pro-
moting effect of the phorbol ester TPA in experimental skin
carcinogenesis may be explained paradoxically by its ability
to increase TGF-P production, which inhibits the growth of
normal keratinocytes and thus favours the outgrowth of
unresponsive neoplastically initiated cells (Parkinson & Bal-
main, 1990). In a wider context, inducers of differentiation
can be regarded as extracellular components of the tumour
suppressor pathway depicted in Figure 2. As such, they are
only likely to be deficient in cancer patients if their produc-
tion is normally limited to a particular stage of development
or if their tissues of origin are defective. With greater
knowledge we can examine these possibilties and determine
whether there are abnormalities which lead to a correctable
cancer susceptibility.
2. The concept of using antisense oligonucleotides to inhibit
tumour specific gene expression is appealing but its problems
have recently been reviewed (Rothenberg et al., 1989). Current
limitations seem to be the expense ofproducing oligomers, their
stability in the body, their uptake by appropriate cells and the
choice ofintracellular targets. Most workers at present seem to
favour mRNA over DNA as a target and there are several
mechanisms by which anti-sense oligonucleotides inhibit
mRNA expression. The sequence specificity ofthis inhibition is
greatest at low concentrations, with non-specific inhibition
becoming apparent at higher concentration. This, I suspect,
may prove a further problem because few transcripts in most
tumour cells will differ sufficiently from those in normal cells to
overcome this lack of discrimination, although there are
exceptions (McManaway et al., 1990). Thus I expect that
antisense oligonucleotides will find their first uses as antiviral
agents, where the pathogen's nucleic acids are distinct from
those ofthe host, and only with greater sophistication will they
prove useful in cancer therapy. A second gambit, the potential
therapeutic use of self-cleaving RNA (ribozymes) has similar
attractions and potential drawbacks.
3. Problems of stability and cellular uptake, if not specificity,
seem less acute if we consider inhibiting oncoprotein activity
rather than oncogene expression, particularly if small molecular
weight synthetic inhibitors can be devised. Moreover, there is
concern, arising from studies on multidrug resistance, that a
tumour cell might overcome inhibition of oncogene or onco-
protein functions by overexpressing the gene and its product.
This potential problem would be minimised if, instead of
inhibiting the oncoprotein directly, its biosynthesis and regula-
tion or the availability of its substrate was modulated.
In practice, a number of oncoproteins function aberrantly
because they no longer respond to the cellular molecules that
regulate their activity, making this an unpromising point of
attack. Biosynthesis seems, however, more vulnerable and, for
example, Ras oncoprotein function could be inhibited by
preventing the covalent attachment of farnesyl residues to the
protein, a metabolic step essential for anchoring the protein in
the plasma membrane. Goldstein and Brown (1990) suggested
that the putative Ras farnesyl-protein transferase would be a
highly specific target for such inhibition whilst, less specifically,
Schafer et al. (1989) achieved a similar end by impeding the
mevalonate pathway with inhibitors of HMG-CoA reductase.
Thetyrosineprotein kinase activities that arecharacteristic of
several oncoproteins located at the cell periphery have been
another focus for inhibitionstudies. Enzymesthat havecatalytic
domains similar to those of prototype tyrosine kinases are
widespread and, among oncoproteins, include some that are
receptors for extracellular ligands and others that are putative
components of second messenger pathways. It was thus my
prejudice that inhibitors of the kinase domain alone would not
discriminate tumour cells from normal and specific inhibitors
would have to recognise the singularity conferred on a given
oncoprotein by theparticular relationship ofitscatalyticmoiety
to otherdomains oftheprotein. Indeed, theisoflavone genistein,
which inhibits a number of tyrosine kinases, and the flavone
quercetin, which inhibits in addition serine and threonine
protein kinases, are both cytotoxic. These two compounds
compete with the phosphate donor ATP, although they are not
simple ATP analogues and may not compete directly with the
ATP binding site on the enzyme (Akiyama et al., 1987).
Specific tyrosine kinase inhibition can, on the other hand, be
displayed by the tyrophostins, a class of synthetic, soluble, low
molecular weight compounds that compete, not with ATP, but
with the tyrosine-containing substrate of the enzymes. Some of
these molecules, patterned on the actinomycete product, erb-
statin, inhibit the epidermal growth factor receptor tyrosine
kinase I02-i0I fold more efficiently than they block the closely
related insulin receptor kinase (Gazit et al., 1989). Moreover,
the consequences ofthis inhibition can be demonstrated in vivo,
where the effects are reversible (Yaish et al., 1988). Thus, despite
the similarity in the catalytic domains of tyrosine kinases, it
seems it will be possible to develop specific inhibitors for
individual enzymes.
4. These results are encouraging but they do not avoid the
concern that, by inhibiting an activated oncoprotein, an essen-
tial normal homologue might also be impaired in tissues other
than the tumour. If, however, the loss of a tumour suppressor
gene function is known to be important in the genesis ofa given
tumour, then the replacement ofthat activity would probably be
less hazardous for normal cells. Our knowledge of tumour
suppressor genes is at present too rudimentary to give promising
instances of this approach. Introduction of the Rb tumour
suppressor gene into retinoblastoma cells can suppress their
tumorigenicity (Huang et al., 1988) but it is, at present, difficult
to see how such gene replacement can be applied to cancer
patients. The replacement of the missing tumour suppressor
protein may be a more feasible option but perhaps the greatest
hope lies with the design of molecules that substitute for the
missing function and are small and stable enough to enter and
act in the cells ofthe tumour. A great deal more must be learned
about tumour suppressor genes before we can realistically
anticipate the development of such compounds.
Putting theory into practice
A recurring theme in my argument has been the need for
more basic knowledge to underpin promising practical appli-
cations. Clearly, clinicians must wait some time yet to see
how our new understanding of cancer will influence their
work, but it is not too early to consider how best to translate
anticipated laboratory advances into clinical practice. A
crucial element in this development will be the availability of
workers with a true understanding of the concepts and tech-
niques of modern molecular and cell biology linked to an
equally full appreciation of the requirements for effective
cancer management. Such personnel are essential if the con-
fluence of laboratory and clinical research is to avoid the
misunderstanding and disappointed expectations which
dampen enthusiasm and encourage conservative attitudes in
both camps.
For some time, the usual way to equip workers for the
difficult role of bridging laboratory and clinical studies has
been to train medical graduates in laboratory science, on the
assumption that they will apply their appreciation of basic
research throughout their subsequent clinical careers. This
stratagem has lately been questioned on the grounds that
clinical demands are too great to be combined with excel-
lence in research and teaching (Arias, 1989). It was proposed,
instead, that the bridge could be formed by laboratory
researchers who received additional training in clinicalBASIC RESEARCH AND THE MANAGEMENT OF CANCER 347
sciences. Such a development is desirable, but as an adjunct
and not an alternative to the informed clinician. The
laboratory worker who understands the problems of patient
management will be invaluable in effecting the close inter-
digitation of 'top up' and 'bottom down' research (Figure 1)
but will still have to rely on the clinician to apply new
knowledge to the patient. Successful practical applications
will become increasingly improbable if other pressures force
clinicians to lose touch with advances in basic research.
Paradoxically, as our knowledge of cancer becomes more
sophisticated it is more, not less, vital for the cancer
physician not to abandon the field to the basic biologist. It is
thus essential that motivated clinicians take time from their
commitments to patients to keep fully abreast of new con-
cepts and technology.
I am grateful to Dr George Birnie for Figure 4 and to Drs Birnie,
Saveria Campo and Ian Pragnell for comments on this manuscript.
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